NCT06145802View on ClinicalTrials.gov

Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (gynecological Tumors)

NARecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

March 9, 2026

Study Completion Date

March 9, 2026

Conditions

Solid TumorGynecological Tumors

Interventions

BIOLOGICAL

GT316

Autologous Tumor Infiltrating Lymphocyte Injection

Trial Locations (1)

Unknown

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

lead

Grit Biotechnology

INDUSTRY

NCT06145802 - Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (gynecological Tumors) | Biotech Hunter | Biotech Hunter